BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33794484)

  • 1. Acute Treatment and 5-Year Follow-up of Longitudinal Deformation of a Bioresorbable Scaffold.
    Creaney CS; Hanratty CG; Christensen MK; Walsh SJ
    J Invasive Cardiol; 2021 Apr; 33(4):E318-E319. PubMed ID: 33794484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography angiography for guiding and follow-up of magnesium-bioresorbable scaffold implantation.
    Opolski MP; Kepka C; Wojakowski W; Witkowski A
    Clin Res Cardiol; 2019 Mar; 108(3):344-346. PubMed ID: 30182164
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
    Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
    Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of late-acquired stent malapposition of drug eluting stents with second generation permanent and biodegradable polymer coatings-A prospective, randomized comparison using optical coherence tomography.
    Roth C; Gangl C; Dalos D; Delle-Karth G; Neunteufl T; Berger R
    J Interv Cardiol; 2018 Dec; 31(6):780-791. PubMed ID: 30479028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial Blood Flow and Coronary Flow Reserve During 3 Years Following Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent Implantation: The VANISH Trial.
    Stuijfzand WJ; Schumacher SP; Driessen RS; Lammertsma AA; Bakker AL; Rijnierse MT; van Rossum AC; van de Ven PM; Nap A; Appelman Y; van Royen N; van Leeuwen MA; Lemkes JS; Raijmakers PG; Knaapen P
    JACC Cardiovasc Interv; 2019 May; 12(10):967-979. PubMed ID: 31029616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Footprint of a Bioresorbable Vascular Scaffold in Computed Tomography Coronary Angiogram at 5-Year Follow-up.
    Vijayvergiya R; Kanabar K; Palanivel R; Lal A; Gupta A
    J Invasive Cardiol; 2020 May; 32(5):E136-E137. PubMed ID: 32357136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very Late Restenosis Following Bioresorbable Scaffold Implantation.
    Okuno T; Yahagi K; Horiuchi Y; Aoki J; Simonton CA; Rapoza R; Saito S; Kimura T; Tanabe K
    JACC Cardiovasc Interv; 2017 Sep; 10(18):e167-e169. PubMed ID: 28866033
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
    Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dislodgement of a magnesium bioresorbable scaffold from the delivery system in the left main: A true "nightmaris".
    Cortés C; Jaguszewski M; Schincariol M; Durán-Cortés MA; Limon U; Gutiérrez-Chico JL
    Cardiol J; 2017; 24(6):700-701. PubMed ID: 29297580
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term intravascular follow-up of coronary bifurcation treatment with Absorb bioresorbable vascular scaffold.
    Vanhaverbeke M; McCutcheon K; Dubois C; Bennett J
    Acta Cardiol; 2018 Aug; 73(4):413-414. PubMed ID: 29277145
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
    Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
    JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
    JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
    Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difference in vascular response between sirolimus-eluting- and everolimus-eluting stents in ostial left circumflex artery after unprotected left main as observed by optical coherence tomography.
    Fujino Y; Attizzani GF; Tahara S; Naganuma T; Takagi K; Yabushita H; Wang W; Tanaka K; Matsumoto T; Kawamoto H; Yamada Y; Amano S; Watanabe Y; Warisawa T; Sato T; Mitomo S; Kurita N; Ishiguro H; Hozawa K; Tsukahara T; Motosuke M; Bezerra HG; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Mar; 230():284-292. PubMed ID: 28065691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treading the risky ground of coronary bifurcation lesion revascularization, the "biodegradable strategy" may represent the lifeline.
    Piraino D; Buccheri D; Andolina G
    Int J Cardiol; 2016 Oct; 221():577-80. PubMed ID: 27420582
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombotic Left Main Coronary Artery Occlusion Treated With Bioresorbable Scaffold.
    Camacho Freire SJ; Gómez Menchero AE; Garrido JR; Rojas ML; Piris RC; Díaz Fernández JF
    Tex Heart Inst J; 2022 Jul; 49(4):. PubMed ID: 35797656
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
    Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
    Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent.
    Schneider VS; Skurk C; Riedel M; Abdelwahed YS; Landmesser U; Leistner DM
    Clin Res Cardiol; 2017 Jul; 106(7):557-559. PubMed ID: 28374059
    [No Abstract]   [Full Text] [Related]  

  • 20. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial.
    Bennett J; Adriaenssens T; Desmet W; Dubois C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):843-853. PubMed ID: 27184586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.